Bharat Biotech, an Indian pharma company, is yet to be added to the Emergency Use List (EUL) by the World Health Organisation (WHO) amid concern of people vaccinated with its COVID vaccine not allowed to travel abroad. The process began in April after the pharma company submitted the required documents. WHO is yet to assess the data. It is also noted that the COVID-19 vaccine made by Bharat Biotech, Covaxin’s phase 3 clinical trial data is yet to be shared with the public, according to a report by Firstpost.

Also read | Delta coronavirus strain induces severe symptoms, may be the deadliest: Report

An interim data of the trials was shared by Bharat Biotech. And according to the pharma company, the vaccine is 78% effective against coronavirus. The Centre said that India was looking forward to WHO’s approval of Covaxin. During a press briefing, a member of NITI Aayog VK Paul said, “We are working with both Bharat Biotech and WHO to make it happen. Data sharing is going on. We are very keen that this milestone is achieved as soon as possible”, reported Firstpost.

“South-East Asia Regional Health Partners’ Forum on COVID-19”, said Indian Foreign Service Officer Harsh Vardhan Shringla, during his address to WHO. “We are also looking forward to WHO’s approval for India’s indigenous vaccine manufactured by Bharat Biotech”, reported Mint.

Also read | Why COVID ‘variants of concern’ found in India were named Kappa, Delta

Bharat Biotech submitted most of the required documents. And the remaining documents are expected to be submitted by June. The company said that it hoped to get the approval of Covaxin by the third or fourth quarter of the year, reported Firstpost. 

“Bharat Biotech, in the past, has been approved by WHO for several other vaccines, so we’re not new to this process. we are aware of it”, Raches Ella, the Head of Business Development and Advocacy of the company, told to the Times of India.